{"filing":{"accession_number":"0001193125-26-352186","cik":"0001936258","ticker":"NAMSW","company_name":"NewAmsterdam Pharma Co N.V.","form":"8-K","filing_date":"2026-08-14","report_date":"2026-08-10","primary_document":"nams-20260810.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1936258/000119312526352186/nams-20260810.htm"},"events":[{"id":27872,"run_id":25448,"accession_number":"0001193125-26-352186","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.92,"summary":"The filing discloses the appointment of Robert W. Gunning as principal accounting officer effective August 10, 2026, succeeding Louise Kooij. While the disclosure also mentions Kooij's departure, the principal action disclosed is Gunning's appointment to the role, supported by detailed biographical information, compensation terms (base salary $375,000, 30% bonus target, RSU and option grants), and offer letter terms. This is a material executive appointment at a pharmaceutical company.","company_name":"NewAmsterdam Pharma Co N.V.","ticker":"NAMSW","filing_date":"2026-08-14","form":"8-K","submitted_at":null,"items":[{"id":29579,"accession_number":"0001193125-26-352186","item_number":"5.02","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The filing discloses the appointment of Robert W. Gunning as principal accounting officer effective August 10, 2026, succeeding Louise Kooij. While the disclosure also mentions Kooij's departure, the principal action disclosed is Gunning's appointment to the role, supported by detailed biographical information, compensation terms (base salary $375,000, 30% bonus target, RSU and option grants), and offer letter terms. This is a material executive appointment at a pharmaceutical company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-14T20:12:22.161076+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":29579,"accession_number":"0001193125-26-352186","item_number":"5.02","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The filing discloses the appointment of Robert W. Gunning as principal accounting officer effective August 10, 2026, succeeding Louise Kooij. While the disclosure also mentions Kooij's departure, the principal action disclosed is Gunning's appointment to the role, supported by detailed biographical information, compensation terms (base salary $375,000, 30% bonus target, RSU and option grants), and offer letter terms. This is a material executive appointment at a pharmaceutical company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-14T20:12:22.161076+00:00","company_name":"NewAmsterdam Pharma Co N.V.","ticker":"NAMSW","filing_date":"2026-08-14"}]}